Low-Level Laser Therapy Ameliorates Disease Progression in a Mouse Model of Alzheimer’s Disease

Dorit Farfara, Hana Tuby, Dorit Trudler, Ella Doron-Mandel, Lidya Maltz, Robert J. Vassar, Dan Frenkel, Uri Oron

Research output: Contribution to journalArticlepeer-review


Low–level laser therapy (LLLT) has been used to treat inflammation, tissue healing, and repair processes. We recently reported that LLLT to the bone marrow (BM) led to proliferation of mesenchymal stem cells (MSCs) and their homing in the ischemic heart suggesting its role in regenerative medicine. The aim of the present study was to investigate the ability of LLLT to stimulate MSCs of autologous BM in order to affect neurological behavior and β-amyloid burden in progressive stages of Alzheimer’s disease (AD) mouse model. MSCs from wild-type mice stimulated with LLLT showed to increase their ability to maturate towards a monocyte lineage and to increase phagocytosis activity towards soluble amyloid beta (Aβ). Furthermore, weekly LLLT to BM of AD mice for 2 months, starting at 4 months of age (progressive stage of AD), improved cognitive capacity and spatial learning, as compared to sham-treated AD mice. Histology revealed a significant reduction in Aβ brain burden. Our results suggest the use of LLLT as a therapeutic application in progressive stages of AD and imply its role in mediating MSC therapy in brain amyloidogenic diseases.

Original languageEnglish
Pages (from-to)430-436
Number of pages7
JournalJournal of Molecular Neuroscience
Issue number2
StatePublished - Feb 2014


  • Alzheimer’s Disease (AD)
  • Amyloid beta (Aβ) bone marrow (BM)
  • Low-level-laser therapy (LLLT)
  • Mesenchymal stem cells (MSC)

All Science Journal Classification (ASJC) codes

  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Low-Level Laser Therapy Ameliorates Disease Progression in a Mouse Model of Alzheimer’s Disease'. Together they form a unique fingerprint.

Cite this